home / stock / inkt / inkt news

INKT News and Press, MiNK Therapeutics Inc.

Stock Information
Company Name: MiNK Therapeutics Inc.
Stock Symbol: INKT
Market: NASDAQ
Website: minktherapeutics.com
Menu
Get INKT Alerts

News, Short Squeeze, Breakout and More Instantly...
INKT - MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc.  (NASDAQ: INKT ), ...
INKT - MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc.  (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today annou...

INKT - MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc.  (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today annou...

INKT - MiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026

2026-03-31 11:03:34 ET More on MiNK Therapeutics MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers Seeking Alpha’s Quant Rating on MiNK Therapeutics Hi...
INKT - MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

2026-03-31 11:02:07 ET MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call March 31, 2026 8:30 AM EDT Company Participants Jennifer Buell - President, CEO & Director Melissa Orilall - Principal Financial Officer ... Read the full article on Seeking Alpha ...

INKT - MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12

2026-03-31 07:34:56 ET More on MiNK Therapeutics MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers Seeking Alpha’s Quant Rating on MiNK Therapeutics Historical earnings data for MiNK Therapeutics Financial informati...

INKT - MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EU C-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncology NIH STTR grant and Mary ...
INKT - MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for ...

INKT - Expected US Company Earnings on Tuesday, March 17th, 2026

Fold Holdings Inc. (FLD) is expected to report $-0.14 for Q4 2025 Modiv Industrial Inc. Class C (MDV) is expected to report $0.37 for Q4 2025 Qfin Holdings Inc. (QFIN) is expected to report $1.13 for Q4 2025 Neo Performance Materials Inc (NOPMF) is expected to report $0.14 for Q4 2025...

INKT - MiNK Therapeutics Partners with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

2026-03-12 06:29:06 ET MiNK Therapeutics (Nasdaq: INKT) , a clinical-stage biopharmaceutical company developing invariant natural killer T (iNKT) cell therapies, has entered a strategic collaboration with C-Further to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatr...
Next 10